NGD-4715

NGD-4715

NGD-4715

Chemical compound

NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1.[1] In animal models it has anxiolytic, antidepressant, and anorectic effects,[2] and it has successfully passed Phase I clinical trials in humans.[3]

Quick Facts Identifiers, CAS Number ...

Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets.[4] All four laboratories were closed and sold, and no employees were retained.[5]

The structure of NGD-4715 has been confused with for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.[6]

References

  1. [1]
    Tarrant J, Hodgetts KJ, Chenard BL, Krause JE, Doller D (2017). "The Discovery of the MCH-1 Receptor Antagonist NGD-4715 for the Potential Treatment of Obesity". Comprehensive Medicinal Chemistry III. pp. 488–515. doi:10.1016/B978-0-12-409547-2.13785-0. ISBN 9780128032015.
  2. [2]
    Chaki S, Kanuma K (2007). "Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders". Drugs of the Future. 32 (9): 809. doi:10.1358/dof.2007.032.09.1131450.
  3. [3]
    "Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity". Business Wire. 2 May 2007.
  4. [4]
    "Neurogen acquired by Ligand Pharmaceuticals". Business Wire. 24 August 2009.
  5. [5]
    "Neurogen to sell Real Estate for $3.5m". Chicago Tribune. 10 November 2009.
  6. [6]
    "NGD-4715". PubChem. U.S. National Library of Medicine.


Stub icon

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article NGD-4715, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.